BRAIN and NERVE－神経研究の進歩76巻5号

2024年05月発行

総説

糖尿病性神経障害の発症メカニズム

著者： 三五一憲¹ 八子英司¹ 高久静香¹ 新見直子¹

所属機関： ¹公益財団法人東京都医学総合研究所糖尿病性神経障害プロジェクト

ページ範囲：P.671 - P.680

文献概要

糖尿病性神経障害は末梢神経疾患の中で最も患者数が多く，また糖尿病の慢性合併症の中で最も早期かつ高頻度に出現する。末梢神経を構成するニューロン，シュワン細胞，血管内皮細胞などの代謝異常が本症の発症・増悪に深く関与することが報告されてきたが，いまだに不明な点も多く疾患修飾薬の開発は遅れている。本論では筆者らの研究を含め，神経障害の発症メカニズム解明および治療戦略に関する最近の知見を紹介する。

参考文献

1）鈴木マリ, 三五一憲: 糖尿病性神経障害. 末梢神経34: 37-44, 2023

2）Mizukami H, Osonoi S: Pathogenesis and molecular treatment strategies of diabetic neuropathy: collateral glucose-utilizing pathways in diabetic polyneuropathy. Int J Mol Sci 22: 94, 2020［doi: 10.3390/ijms22010094］

3）Niimi N, Yako H, Takaku S, Chung SK, Sango K: Aldose reductase and the polyol pathway in Schwann cells: old and new problems. Int J Mol Sci 22: 1031, 2021［doi: 10.3390/ijms22031031］

4）Ohno RI, Ichimaru K, Tanaka S, Sugawa H, Katsuta N, et al: Glucoselysine is derived from fructose and accumulates in the eye lens of diabetic rats. J Biol Chem 294: 17326-17338, 2019

5）Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, et al: Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 25: 818-825, 2008

6）Sano H, Nakamura A, Yamane M, Niwa H, Nishimura T, et al: The polyol pathway is an evolutionarily conserved system for sensing glucose uptake. PLoS Biol 20: e3001678, 2022［doi: 10.1371/journal.pbio.3001678］

7）Jang I, Kim HB, Seo H, Kim JY, Choi H, et al: O-GlcNAcylation of eIF2α regulates the phospho-eIF2α-mediated ER stress response. Biochim Biophys Acta 1853: 1860-1869, 2015

8）Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, et al: Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55: 1946-1953, 2006

9）Mizukami H, Osonoi S, Takaku S, Yamagishi SI, Ogasawara S, et al: Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway. Brain Commun 2: fcaa168, 2020［doi: 10.1093/braincomms/fcaa168］

10）Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, et al: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48: 2090-2095, 1999

11）Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, et al; MBBQ Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 27: 1164-1180, 2005

12）Yako H, Niimi N, Kato A, Takaku S, Tatsumi Y, et al: Role of pyruvate in maintaining cell viability and energy production under high-glucose conditions. Sci Rep 11: 18910, 2021［doi: 10.1038/s41598-021-98082-w］

13）Yako H, Niimi N, Takaku S, Sango K: Advantages of omics approaches for elucidating metabolic changes in diabetic peripheral neuropathy. Front Endocrinol (Lausanne) 14: 1208441, 2023［doi: 10.3389/fendo.2023.1208441］

14）赤嶺友代, 西村理明, 三五一憲: 糖尿病性神経障害の成因: グリケーション. 月刊糖尿病124: 26-31, 2020

15）Hidmark A, Fleming T, Vittas S, Mendler M, Deshpande D, et al: A new paradigm to understand and treat diabetic neuropathy. Exp Clin Endocrinol Diabetes 122: 201-207, 2014

16）Nishizawa Y, Wada R, Baba M, Takeuchi M, Hanyu-Itabashi C, et al: Neuropathy induced by exogenously administered advanced glycation end-products in rats. J Diabetes Investig 1: 40-49, 2010

17）Duran-Jimenez B, Dobler D, Moffatt S, Rabbani N, Streuli CH, et al: Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 58: 2893-2903, 2009

18）Shimizu F, Sano Y, Haruki H, Kanda T: Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 54: 1517-1526, 2011

19）Osonoi S, Mizukami H, Takeuchi Y, Sugawa H, Ogasawara S, et al: RAGE activation in macrophages and development of experimental diabetic polyneuropathy. JCI Insight 7: e160555, 2022［doi: 10.1172/jci.insight.160555］

20）Hur J, Sullivan KA, Schuyler AD, Hong Y, Pande M, et al: Literature-based discovery of diabetes- and ROS-related targets. BMC Med Genomics 3: 49, 2010［doi: 10.1186/1755-8794-3-49］

21）Lin Q, Li K, Chen Y, Xie J, Wu C, et al: Oxidative stress in diabetic peripheral neuropathy: pathway and mechanism-based treatment. Mol Neurobiol 60: 4574-4594, 2023

22）Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, et al: Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34: 2054-2060, 2011

23）Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C, et al: Efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, and carnitine for 12 months in patients with diabetic neuropathy. Nutrients 12: 3254, 2020［doi: 10.3390/nu12113254］

24）Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, et al: Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov 2: 15072, 2016［doi: 10.1038/cddiscovery.2015.72］

25）Kato A, Tatsumi Y, Yako H, Sango K, Himeto T, et al: Recurrent short-term hypoglycemia and hyperglycemia induce apoptosis and oxidative stress via the ER stress response in immortalized adult mouse Schwann (IMS32) cells. Neurosci Res 147: 26-32, 2019［doi: 10.1016/j.neures.2018.11.004］

26）加藤宏一, 三五一憲: 糖尿病性神経障害の病態生理と治療薬の開発. 日病態生理会誌32: 23-25, 2023

27）Nagai Y, Matoba K, Takeda Y, Yako H, Akamine T, et al: Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism. Kidney Int 102: 536-545, 2022

28）Kanazawa Y, Takahashi-Fujigasaki J, Ishizawa S, Takabayashi N, Ishibashi K, et al: The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells. Exp Neurol 247: 438-446, 2013

29）Tsukamoto M, Niimi N, Sango K, Takaku S, Kanazawa Y, et al: Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and PI3 kinase/RhoA signaling. Histochem Cell Biol 144: 249-259, 2015

30）Takaku S, Tsukamoto M, Niimi N, Yako H, Sango K: Exendin-4 promotes Schwann cell survival/migration and myelination in vitro. Int J Mol Sci 22: 2971, 2021［doi: 10.3390/ijms22062971］

31）Xiang Q, Liu Y, Chen L: Saikosaponin d (SSD) alleviates diabetic peripheral neuropathy by regulating the AQP1/RhoA/ROCK signaling in streptozotocin-induced diabetic rats. Acta Diabetol 60: 805-815, 2023

32）Holeček M: Role of impaired glycolysis in perturbations of amino acid metabolism in diabetes mellitus. Int J Mol Sci 24: 1724, 2023［doi: 10.3390/ijms24021724］

33）Handzlik MK, Gengatharan JM, Frizzi KE, McGregor GH, Martino C, et al: Insulin-regulated serine and lipid metabolism drive peripheral neuropathy. Nature 614: 118-124, 2023

34）Suzuki M, Kuromi H, Shindo M, Sakata N, Niimi N, et al: A Drosophila model of diabetic neuropathy reveals a crucial role of proteasome activity in the glia. iScience 26: 106997, 2023［doi: 10.1016/j.isci.2023.106997］

35）Cortese A, Zhu Y, Rebelo AP, Negri S, Courel S, et al: Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nature Genet 52: 473-481, 2020

36）湯地美佳, 安藤匡宏, 吉村明子, 谷口雄大, 武井 潤, 他: Sorbitol Dehydrogenase（SORD）遺伝子変異を有する遺伝性ニューロパチーの5家系. 第63回日本神経学会学術大会抄録集 Pj-024-2, 2022

37）Zhu Y, Lobato AG, Rebelo AP, Canic T, Ortiz-Vega N, et al: Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency. JCI Insight 8: e164954, 2023［doi: 10.1172/jci.insight.164954］